TS 155-2
(Synonyms: JBIR 100) 目录号 : GC17423An antihypertensive antibiotic
Cas No.:1314486-37-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
TS 155-2, is a macrocyclic lactone related to hygrolidin, is produced by a different Streptomyces species found in oil. It blocks thrombin-evoked calcium (Ca2+) entry into cells. TS155-2 exerts hypotensive, anti-platelet, anti-ischaemic and anti-inflammatory activity showed on the original patent, however, no literature investigation of TS155-2 is available.
A rapid increase in cytosolic Ca2+ is related to the signal transduction events following the induction of thrombin in a wide range of cell types which include fibroblasts, platelets, megakaryocytes, endothelium and smooth muscle. Thrombin-stimulated Ca2+ mobilization has been shown to be involved in both Ca2+ release from internal storage sites and Ca2+influx and has been extensively studied in human platelets. Thrombin triggers phospholipase C resulting in the rapid generation of inositol 1,4,5-trisphosphate (IP3), which elicits the release of Ca2+ from IP3-sensitive stores. However, the thrombin-induced Ca2+ influx is still an area of contention [1].
In vitro: Up to now, in vitro study of TS 155-2 is still in the development stage.
In vivo: Up to now, in vivo study of TS 155-2 is still in the development stage.
Reference:
[1]. Somasundaram, B., Mason, M., & Mahaut-Smith, M. Thrombin-dependent calcium signalling in single human erythroleukaemia cells. The Journal of Physiology.1997;501(3):485-495.
| Cas No. | 1314486-37-7 | SDF | |
| 别名 | JBIR 100 | ||
| 化学名 | 2E-butenedioic acid-1-[(2R,4R,5S,6R)-tetrahydro-2-hydroxy-2-[(1S,2R,3S)-2-hydroxy-3-[(2R,3S,4E,6E,9S,10S,11R,12E,14E)-10-hydroxy-3-methoxy-7,9,11,13,15-pentamethyl-16-oxooxacyclohexadeca-4,6,12,14-tetraen-2-yl]-1-methylbutyl]-5-methyl-6-(1-methylethyl)-2H | ||
| Canonical SMILES | C[C@H]([C@]1(O)O[C@H](C(C)C)[C@@H](C)[C@H](OC(/C=C/C(O)=O)=O)C1)[C@H](O)[C@@H]([C@](OC(/C(C)=C/C(C)=C/[C@@H](C)[C@@H](O)[C@@H](C)C2)=O)([H])[C@H](/C=C/C=C2\C)OC)C | ||
| 分子式 | C39H60O11 | 分子量 | 704.9 |
| 溶解度 | DMF: soluble,DMSO: soluble,Ethanol: soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.4186 mL | 7.0932 mL | 14.1864 mL |
| 5 mM | 0.2837 mL | 1.4186 mL | 2.8373 mL |
| 10 mM | 0.1419 mL | 0.7093 mL | 1.4186 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。